Literature DB >> 34571290

Synthetic receptors for logic gated T cell recognition and function.

Sylvain Simon1, Grace Bugos2, Alex I Salter3, Stanley R Riddell4.   

Abstract

Adoptive cell therapy with T cells engineered with customized receptors that redirect antigen specificity to cancer cells has emerged as an effective therapeutic approach for many malignancies. Toxicity due to on target or off target effects, antigen heterogeneity on cancer cells, and acquired T cell dysfunction have been identified as barriers that can hinder successful therapy. This review will discuss recent advances in T cell engineering that have enabled the application of logic gates in T cells that can mimic the integration of natural signaling pathways and act in a cell intrinsic or extrinsic fashion to precisely target tumor cells and regulate effector functions, potentially overcoming these barriers to effective therapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34571290      PMCID: PMC8901444          DOI: 10.1016/j.coi.2021.09.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  81 in total

1.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

2.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

3.  Studies on O-glycans of Plasmodium-falciparum-infected human erythrocytes. Evidence for O-GlcNAc and O-GlcNAc-transferase in malaria parasites.

Authors:  A Dieckmann-Schuppert; E Bause; R T Schwarz
Journal:  Eur J Biochem       Date:  1993-09-15

4.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.

Authors:  Ko Kudo; Chihaya Imai; Paolo Lorenzini; Takahiro Kamiya; Koji Kono; Andrew M Davidoff; Wee Joo Chng; Dario Campana
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

5.  Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

Authors:  Ruth Dannenfelser; Gregory M Allen; Benjamin VanderSluis; Ashley K Koegel; Sarah Levinson; Sierra R Stark; Vicky Yao; Alicja Tadych; Olga G Troyanskaya; Wendell A Lim
Journal:  Cell Syst       Date:  2020-09-10       Impact factor: 10.304

6.  Precise T cell recognition programs designed by transcriptionally linking multiple receptors.

Authors:  Jasper Z Williams; Greg M Allen; Devan Shah; Igal S Sterin; Ki H Kim; Vivian P Garcia; Gavin E Shavey; Wei Yu; Cristina Puig-Saus; Jennifer Tsoi; Antoni Ribas; Kole T Roybal; Wendell A Lim
Journal:  Science       Date:  2020-11-27       Impact factor: 47.728

7.  Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.

Authors:  Martin Wermke; Sabrina Kraus; Armin Ehninger; Ralf C Bargou; Maria-Elisabeth Goebeler; Jan Moritz Middeke; Carla Kreissig; Malte von Bonin; Jan Koedam; Michael Pehl; Martin Bornhäuser; Hermann Einsele; Gerhard Ehninger; Marc Cartellieri
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

8.  SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.

Authors:  Axel Hyrenius-Wittsten; Yang Su; Minhee Park; Julie M Garcia; Josef Alavi; Nathaniel Perry; Garrett Montgomery; Bin Liu; Kole T Roybal
Journal:  Sci Transl Med       Date:  2021-04-28       Impact factor: 17.956

Review 9.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.

Authors:  Marina Martinez; Edmund Kyung Moon
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

10.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.